Disc Medicine, Inc.
- Open
- 78.56
- Day high
- 79.61
- Day low
- 75.88
- Prev close
- 78.65
- Volume
- 25K
- Mkt cap
- $3.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.7
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$11.4M over the last 3 months (0 open-market buys, 22 sales)
- 🏛Institutions accumulating (13F)
Disc Medicine, Inc. (IRON) is a Healthcare company listed on NASDAQ. The stock is up 28% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 22 sales (SEC Form 4).
Disc Medicine, Inc. (IRON) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
IRON earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 30, 2026 | $-1.71 | $-1.54 | +9.9% | — | — |
| May 5, 2026 | $-1.55 | $-1.65 | -6.5% | — | — |
| Feb 26, 2026 | $-1.69 | $-1.71 | -1.5% | $-20M | — |
| Nov 6, 2025 | $-1.48 | $-1.77 | -19.6% | — | — |
| Aug 7, 2025 | $-1.17 | $-1.58 | -35.0% | — | — |
| May 7, 2025 | $-0.99 | $-1.02 | -3.0% | — | — |
| Feb 27, 2025 | $-1.06 | $-0.98 | +7.5% | — | — |
| Aug 8, 2024 | $-1.11 | $-1.03 | +7.2% | — | — |
| May 9, 2024 | $-1.00 | $-1.09 | -9.0% | — | — |
| Mar 21, 2024 | $-0.75 | $-0.97 | -29.3% | — | — |
| Nov 9, 2023 | $-0.75 | $-0.58 | +22.7% | — | — |
| Aug 11, 2023 | $-0.88 | $-0.74 | +15.9% | — | — |
IRON insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 26, 2026 | Yu Jonathan Yen-Wenofficer: Chief Operating Officer | Option | 8,796 | $13.50 |
| Aug 26, 2026 | Yu Jonathan Yen-Wenofficer: Chief Operating Officer | Sell | 8,796 | $83.12 |
| Aug 26, 2026 | Yu Jonathan Yen-Wenofficer: Chief Operating Officer | Sell | 300 | $82.53 |
| Aug 26, 2026 | Yu Jonathan Yen-Wenofficer: Chief Operating Officer | Option | 300 | $13.50 |
| Aug 18, 2026 | Quisel John Ddirector, officer: Chief Executive Officer | Sell | 12,712 | $79.20 |
| Aug 18, 2026 | Quisel John Ddirector, officer: Chief Executive Officer | Sell | 11,888 | $79.84 |
| Aug 18, 2026 | Quisel John Ddirector, officer: Chief Executive Officer | Option | 33,000 | $13.50 |
| Aug 18, 2026 | Quisel John Ddirector, officer: Chief Executive Officer | Sell | 8,400 | $78.11 |
| Aug 14, 2026 | Yu Jonathan Yen-Wenofficer: Chief Operating Officer | Sell | 804 | $82.64 |
| Aug 14, 2026 | Yu Jonathan Yen-Wenofficer: Chief Operating Officer | Option | 804 | $13.50 |
| Aug 7, 2026 | Khara Rahulofficer: Chief Legal Officer | Sell | 5,000 | $80.00 |
| Aug 7, 2026 | Khara Rahulofficer: Chief Legal Officer | Option | 5,000 | $14.69 |
| Jul 14, 2026 | Quisel John Ddirector, officer: Chief Executive Officer | Sell | 9,704 | $74.27 |
| Jul 14, 2026 | Quisel John Ddirector, officer: Chief Executive Officer | Option | 7,416 | $13.50 |
| Jul 14, 2026 | Quisel John Ddirector, officer: Chief Executive Officer | Option | 25,584 | $9.86 |
Source: IRON SEC Form 4 filings, latest Aug 26, 2026. For informational purposes only — not investment advice.
See the full IRON insider & 13F page →Disc Medicine, Inc. company profile
Overview
Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biotechnology company founded and based in Watertown, Massachusetts. The company went public in August 2020 and focuses on developing novel treatments for patients suffering from serious blood disorders, specifically hematologic diseases. Disc Medicine builds its therapeutic pipeline by targeting fundamental biological pathways related to red blood cell biology, with particular emphasis on heme biosynthesis and iron homeostasis - the processes by which the body produces red blood cells and manages iron levels.
Business
Disc Medicine operates in the biotechnology sector, specifically focusing on hematologic diseases - disorders that affect blood, bone marrow, and lymphatic systems. These conditions can range from anemia and iron deficiency disorders to more complex blood cancers and inherited blood diseases. The company's core approach centers on two critical biological pathways. Heme biosynthesis is the process by which cells produce heme, the iron-containing component of hemoglobin that allows red blood cells to carry oxygen throughout the body. When this process is disrupted, it can lead to various forms of anemia and other blood disorders. Iron homeostasis refers to how the body maintains proper iron levels - too little iron leads to anemia, while too much can cause organ damage. Disc Medicine develops small molecule drugs and other therapeutic candidates that can modulate these pathways to treat patients with serious hematologic conditions. The company's pipeline includes treatments for conditions such as anemia of chronic disease, beta-thalassemia, sickle cell disease, and other inherited or acquired blood disorders. As a clinical-stage company, Disc Medicine currently generates no revenue from product sales, as its therapeutic candidates are still undergoing clinical trials and have not yet received regulatory approval for commercial use.
Revenue model
As a clinical-stage biotechnology company, Disc Medicine currently operates on a research and development model without generating revenue from product sales. The company funds its operations through equity financing, including its initial public offering and subsequent stock offerings, as well as potential partnerships and licensing agreements. The company's future revenue model will likely center on product sales of approved therapeutics, with potential additional income from licensing agreements and royalty payments from partners who may help commercialize treatments in specific markets or geographies. The paying customers would primarily be healthcare systems, hospitals, specialty clinics, and patients (through insurance coverage) who need treatments for hematologic diseases. Several factors could significantly impact Disc Medicine's future profitability. Regulatory approval timelines represent the most critical factor - delays in clinical trials or FDA approval processes directly affect when the company can begin generating revenue. Clinical trial success rates determine whether the substantial R&D investments will yield marketable products. Competition from larger pharmaceutical companies developing treatments for similar conditions could affect market share and pricing power. Healthcare reimbursement policies and insurance coverage decisions will influence patient access and pricing strategies. Additionally, manufacturing and supply chain costs will impact gross margins once products reach market, while the company's ability to secure favorable partnership terms could provide non-dilutive funding and reduce commercialization risks.
Competitive moat
Disc Medicine's competitive position is relatively modest, typical of early-stage biotechnology companies. The company's primary potential moat lies in its specialized scientific expertise in heme biosynthesis and iron homeostasis pathways, which requires deep understanding of complex biological mechanisms that are not easily replicated. The company may develop intellectual property protection through patents on its therapeutic compounds and treatment methods, though the strength and breadth of this protection remains to be established as clinical programs advance. Additionally, if successful in clinical trials, Disc Medicine could benefit from regulatory exclusivity periods that prevent generic competition for several years after approval. However, the company faces significant competitive threats. Large pharmaceutical companies with substantially greater resources are actively developing treatments for hematologic diseases and could potentially out-compete Disc Medicine through faster development timelines, broader clinical programs, or superior commercial capabilities. The biotechnology sector also sees frequent scientific breakthroughs that can render existing approaches obsolete. Furthermore, regulatory risks mean that even promising treatments may fail to gain approval, while successful competitors could capture market share before Disc Medicine's products reach commercialization. The company's moat is therefore quite narrow and largely dependent on successful execution of its clinical development programs and the uniqueness of its scientific approach.
Risks & safety
Disc Medicine maintains a relatively strong financial position for a clinical-stage biotechnology company, though it faces typical cash burn challenges. • Cash position: $122.7 million in cash and short-term investments as of Q1 2025, down from $192.4 million at end of 2024 • Cash burn: Free cash flow of -$42.2 million in Q1 2025, suggesting approximately 3 years of runway at current burn rate • Debt levels: Minimal debt with debt-to-equity ratio of 0.046, indicating low financial leverage risk • Liquidity: Exceptional current ratio of 37.7x and quick ratio of 37.7x, demonstrating strong short-term liquidity • Valuation metrics: Trading at 2.5x price-to-book ratio, which is reasonable for a clinical-stage biotech • Solvency risk: Low near-term bankruptcy risk given strong balance sheet, though long-term viability depends on clinical success or additional financing • Other considerations: No revenue generation creates dependency on capital markets for funding; increasing quarterly losses from $26-29 million to $34 million indicate rising R&D expenses as programs advance
Recent development
Based on the available financial data, Disc Medicine has been in a phase of intensive research and development investment over the past few years. The company's operating expenses have increased significantly, with annual losses growing from $46.8 million in 2022 to $109.4 million in 2024, indicating substantial scaling of clinical development activities. The company's cash burn has also accelerated, with quarterly free cash flow losses increasing from approximately $15-17 million in mid-2024 to over $42 million in Q1 2025. This suggests the company has advanced multiple clinical programs simultaneously or moved into more expensive later-stage trials. The substantial cash position built up through 2024 (reaching over $280 million in Q2 2024) provided the financial foundation for this expanded development effort. The increasing pace of spending indicates Disc Medicine is likely advancing its lead therapeutic candidates through critical clinical milestones, potentially including Phase 2 or Phase 3 trials that require larger patient populations and more extensive infrastructure. The company appears to be executing on its strategy of building a comprehensive pipeline targeting heme biosynthesis and iron homeostasis pathways, though specific program details and clinical results are not available from the financial statements alone.
IRON company profile · for informational purposes only — not investment advice.
Track IRON with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free